Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04786457 · ClinicalTrials.gov registry record · Phase 1
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
A Phase 1 study of Dengue, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04786457: Completed Phase 1 study of Dengue, sponsored by University of Maryland, Baltimore.
NCT04786457 is a Phase 1 study of Dengue that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 10 participants, below the 3,980-participant average among 9 other Dengue trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04786457, a Phase 1 study of Dengue, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test the protection of volunteers previously vaccinated with Tetravalent Dengue Virus (TDEN) Purified Inactivated Vaccine (PIV) with alum and boosted with TDEN live attenuated vaccine (LAV) formulation against a weakened form of an experimental dengue virus challenge. The Investigators will also include people that have not received the study vaccine. The Investigators are collecting information about how the vaccine protects against a dengue virus challenge as well as adding to knowledge about the safety of the challenge.
Primary Outcome
Number of Participants with Solicited Injection Site Erythema - solicited injection site adverse event until 7 days post virus inoculation
Conditions Studied
Interventions
- BIOLOGICAL Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Study Locations (1)
Maryland
- University of Maryland, Baltimore, Center for Vaccine Development and Global Health - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2021-07-09 |
| Phase | Phase 1 |
What the finished NCT04786457 record still lists
NCT04786457 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 3,980-participant average among 9 other Dengue trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 1 intervention - of which Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) is the first listed.
NCT04786457 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04786457 about?
NCT04786457 is a clinical study titled "ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)". The purpose of this research study is to test the protection of volunteers previously vaccinated with Tetravalent Dengue Virus (TDEN) Purified Inactivated Vaccine (PIV) with alum and boosted with TDEN live attenuated vaccine (LAV) formulation against a weakened form of an experimental dengue virus c...
What is the current status of trial NCT04786457?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-11-30. Estimated completion is 2021-07-09.
What conditions does trial NCT04786457 study?
This clinical trial studies the following conditions: Dengue.
What interventions are being tested in trial NCT04786457?
The interventions under investigation include: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04786457?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04786457 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dengue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04786457's enrollment target sits among peer trials
10 10th of 9 the lowest of 9 other Dengue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dengue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
COMPLETED · Phase 1
-
TDENV PIV and LAV Dengue Prime-boost Strategy
COMPLETED · Phase 1
-
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
COMPLETED · Phase 1
-
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
COMPLETED · Phase 1
-
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
COMPLETED · Phase 1
-
Tetravalent Chimeric Dengue Vaccine Trial
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI